BioNetwork Asia 2011 was a great success! Hear what our customers have to say!
To be part of the 2012 event please contact Jaime Ng at firstname.lastname@example.org“I think the theme of the event was very timely and the speakers and panelists really made the event worthwhile. Well done.”Professor Lee Eng Hin
, Executive Director, BMRC, Agency for Science, Technology and Research (A*STAR)“Excellent forum, well organized. If you want to know what is happening in Asia in Bio field then you have to be at Bionetwork Asia.”Shakil Ohara,
Business Strategy Director, Pacific Asia, Abbott “I found the Bionetwork Asia very stimulating due to the quality of the participants and the structure of the event. I particularly found some of the panel discussions very insightful. The networking meetings were very efficiently organized. Great job done by the organizing team!”
Director, Strategy & Business Development, Pfizer“The conference was well structured – the pitch competition worked well and Simon did a great job at chairing the sessions. Generally, the audience and panellists were quite strong. Lunch roundtables worked really well (with the right facilitator) – people got very engaged and provided good structure to the lunchtime session. Well done.”Carl Firth,
Chief Executive Officer & Founder, ASLAN Pharmaceuticals“BioNetwork Asia 2011 brought many important stakeholders who will have an impact on the Asian pharmaceutical industry landscape in the next few years. It was an excellent platform to get a feel of what is happening around the region and what to expect in the foreseeable future. The topics of discussion were spot-on, insightful and dealt with many important issues that is relevant not only for Asia but the international community as well. I’m looking forward to the next BioNetwork Asia event.” Brian Lam,
Director for Business Development, Inviragen“I attended Bionetwork Asia following recommendations from colleagues. The meeting was very informative regarding Asian market and trends for the future. As European we are not perfectly informed or aware about the real situation. In addition to this I was able to make very interesting contacts due to the “human size” of the event which will be helpful for the future.”David Deperthes,
President and C.E.O, Med Discovery SA“The event was very useful with interesting topics. Keep up the good job.”Shermal Perera,
Managing Director, SIOGEN Biotech“Well-organized event with good speakers who were well-prepared. The event was not too large making it possible to do networking and have meaningful conversations. Dinner and cocktails were splendidly arranged.”Sanjay Sehgal,
Managing Partner & CEO, East West Capital Partners“Bionetwork Asia was a wonderful event—well organized and quite fruitful. You may find many experienced executives here and share with their insights and perspectives to the biopharma industry and investment opportunities. The well-selected topics were valuable to all delegates, from startups, MNCs, or VCs.”Wu Ke,
President, BravoBio“Very high quality meeting where top level people interacted very openly with each other in a great deal and financing atmosphere.”Patrick Doyle,
President, Business & Corporate, Kareus Therapeutics SA“The meeting fostered strong networking across Asia Pac and attempted to distil a vision of the future from a complex mixture of changing big pharma strategy and a fast growing Asian CRO and biotech sector.”Mark McHale,
CSO, ASLAN Pharmaceuticals“I enjoyed the conference.”Peter Cichon,
Regional Strategic Development Manager, Bayerhealthcare“It was an intimate conference where people were able to meet and get to know each other and build up some relationships as well. Good job!”Michael Lin,
Patent Attorney, Marks & Clerk
Asia Pacific is taking the lead in the race to win the largest share of the global pharmaceutical industry, led by growth in China, India and Singapore. Reports have shown that both multinational companies (MNCs) and domestic pharma believe Asia will eclipse North America and Europe. A phenomenal increase in East-West partnerships are being forged between pharmas, biotechs, governments and academics in the hope of driving further and greater innovation.
However, though Asia is becoming the new centre of gravity, research has shown that many of these companies are still worried about intellectual property rights and legal risk in this region, especially in China and India - the two world's most attractive Asian emerging markets for bio-pharmaceuticals and healthcare in general.
BioNetwork Asia 2011 explored in detail what are some of the growth potentials and challenges conducting partnerships in Asia that are impacting the dynamics of the pharma industry – setting attendees up with the right strategies and bringing them the right partners for collaboration to increase their pipelines and gain competitive edge among their peers for the coming 2012 and beyond. The next question is not whether the opportunity has arrived, but more a case of will you grasp this chance to learn from these 30+ industry experts and network with the right people? - Read the full agenda
. WBR’s largest BioNetwork event in Asia - BioNetwork Asia 2011 brought together OVER 300 participants globally
By attending BioNetwork Asia in Singapore, attendees positioned themselves at the front of the pharma race and left with a complete understanding on the most important issues and solutions, including:
- Asian pharma industry trends and growth potential in the next 5 years
- The potential of Public Private Partnership (PPP) in Asia
- Effective deal making between East-West
- Debate on government funded projects – blessing or a curse?
- Tackling pricing and reimbursement issues in China
- New model for sharing risks and reaping rewards
- Evaluating new projects and innovations from the perspective of a biotech
- Opportunities for pharmaceutical R&D innovation and partnership in Asia
- Harnessing academia-industry partnerships to drive drug discovery
- The perfect pitch - advice from our panel of experts for crafting your perfect pitch
Lee Eng Hin
Executive Director, BMRC, Agency for Science, Technology and Research (A*STAR)
Dr Lee is currently the Executive Director of the Biomedical Research Council, Agency for Science, Technology and Research, Singapore. He holds a conc [read more]
Executive Director, Global Licensing & Business Development, Boehringer Ingelheim
As Executive Director & Head, Global Licensing - Commercial Opportunities, Dr. Hill's responsibilities include identifying and executi [read more]
AN EXCLUSIVE ONE-ON-ONE MEETINGS FOR ALL 2 DAYS
The conference featured private, pre-arranged ONE-ON-ONE meetings between senior-level executives using state-of-the-art partnering software. The format and selective nature of the conference made this the premier dedicated partnering event in Asia where attendees can privately discussed the specifics of their companies, their goals and their compounds.
23 Aug 2010, Tuesday
Session I: Addressed IP Licensing issuies in collaboration deals and a co-development partnerships in China
Session II: Identified other commercial and legal considerations in partnering with local companies in China
Masterclass Leader: Michael Lin, Patent Attorney, Marks & Clerk